, randomized, open-label trial evaluated the safety and efficacy of early EVR initiation. Patients treated with corticosteroids, TAC, and basiliximab were randomized (2:1) to receive EVR (1.5 mg twice daily) on day 8 and to gradually minimize or withdraw TAC when EVR was stable at >5 ng/mL or to continue TAC at 6-12 ng/mL. The primary endpoint was the proportion of treated biopsy-proven acute rejection (tBPAR)-free patients at 3 months after transplant. As secondary endpoints, composite tBPAR plus graft/patient loss rate, renal function, TAC discontinuation rate, and adverse events were assessed. A total of 93 patients were treated with EVR, and 47 were controls. After 3 months from transplantation, 87.1% of patients with EVR and 95.7% of controls were tBPAR-free (P = 0.09); composite endpoint-free patients with EVR were 85% (versus 94%; P = 0.15). Also at 3 months, 37.6% patients were in monotherapy with EVR, and the tBPAR rate was 11.4%. Estimated glomerular filtration rate was significantly higher with EVR, as early as 2 weeks after randomization. In the study group, higher rates of dyslipidemia (15% versus 6.4%), wound complication (18.3% versus 0%), and incisional hernia (25.8% versus 6.4%) were observed, whereas neurological disorders were more frequent in the control group (13.9% versus 31.9%; P < 0.05). In conclusion, an early EVR introduction and TAC minimization may represent a suitable approach when immediate preservation of renal function is crucial.
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evidence has demonstrated that these effects can be reversed or minimized if reduced exposure to CNI agents is implemented early after transplantation. (5, 6) In contrast, late CNI-induced chronic renal failure is associated with interstitial nephritis and is usually irreversible. (7) Recent evidence indicates that the combination of CNIs with mammalian target of rapamycin (mTOR) inhibitors guarantees a proper immunosuppression and offers the opportunity to minimize CNI exposure, (8) (9) (10) (11) thus providing a rational basis to reduce or discontinue CNI exposure before an irreversible renal deterioration occurs. Many observational studies reported that combining everolimus (EVR) with a low dose of tacrolimus (TAC) within 4 weeks after LT contributed to preserving kidney function. (11) (12) (13) This observation was strengthened by the results of a few well-designed, randomized, controlled trials on early EVR initiation (1 month after transplant) with subsequent CNI minimization or discontinuation. (5, 8, 14, 15) However, very early (between 1 week and 1 month) EVR-facilitated CNI reduction or discontinuation has not been deeply investigated because of concerns of increased rejection rate (16) and evidence of an increased risk of hepatic artery thrombosis (sirolimus).
The aim of this prospective randomized study was to evaluate the efficacy and safety of an early (postoperative day [POD] 7) EVR initiation and TAC minimization compared with a standard TAC regimen after de novo LT.
Patients and Methods

stUDY Design
We conducted a 24-month investigator-driven, prospective, multicenter, randomized, parallel-group, open-label, classical single-stage phase 2 study on adult recipients of a primary liver graft. The study (NCT01423708) was conducted in 7 Italian transplant centers and performed according to the Declaration of Helsinki. Written informed consent was obtained from all patients after approval from the institutional review board at each center (institutional review board number 1956P, University of Padua).
All patients received an immunosuppressive regimen based on corticosteroids (500 mg on the day of surgery and tapered to 20 mg daily from POD 1 until month 3), basiliximab (Simulect, Novartis, Origgio [VA] , Italy) 20 mg intravenously (IV) on the day of surgery and on POD 4, and TAC within POD 3. The schedule and dosing are reported in Fig. 1 .
inclUsiOn/eXclUsiOn criteria
Adult patients (18-70 years) who had received primary full-sized or split LT from a deceased donor were considered for the current study if consenting. To be eligible for randomization, patients needed acceptable graft function (defined as absence of primary dysfunction) (17) at day 7, platelet count >40,000/mm 3 , white blood cell count >2000/mm 3 , hemoglobin (Hb) >7 g/dL, and cold ischemia time (CIT) <12 hours.
Exclusion criteria were as follows: history of cancer (except nonmetastatic skin cancers and hepatocellular carcinoma [HCC] within transplantable criteria), combined kidney-liver transplant, retransplantation, living donor LT, and United Network for Organ Sharing status 1 patients.
ranDOMiZatiOn
One week after transplantation, patients were randomized into 2 arms using a 2:1 ratio. concentration of 5 ng/mL, and then dosing was adjusted to maintain a trough concentration between 6 and 12 ng/mL. When EVR trough levels were stable at >5 ng/mL, TAC was gradually decreased (<5 ng/ mL) and discontinued within 30 days after transplantation. TAC withdrawal within 1 month had to be avoided in cases of tBPAR, when a trough level of 8 ng/mL within 20 days from LT was not reached, or when potentially EVR-related AEs occurred. In case of significant AEs, the investigators were authorized by protocol to discontinue EVR administration for a maximum of 7 consecutive days. Longer discontinuation periods would result in patient drop-out. In the control group, patients who received a standard immunosuppression with TAC were included. TAC trough concentration was maintained between 6 and 12 ng/mL until the end of the study. Introduction of any other immunosuppressive drugs other than those mentioned here was considered a deviation from protocol. Per protocol biopsies were recommended only for hepatitis C virus (HCV) patients at 12 months and when graft rejection was suspected.
stUDY enDpOints
The primary endpoint was the proportion of patients who did not show a treated biopsy-proven acute rejection (tBPAR) at month 3. tBPAR was defined as acute rejection with a locally confirmed rejection activity index ≥3 according to the Banff 1997 criteria (18) treated with antirejection therapy. The secondary endpoints were as follows: the composite efficacy failure rate (tBPAR, graft loss, or death) at 3, 12, and 24 months after transplantation (excluding events before randomization); renal function evaluation assessed by estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD)-4 formula at 1, 6, 12, and 24 months; the rate of TAC discontinuation at 24 months in the study group; and AEs in a 24-month follow-up.
saFetY, tOleraBilitY, anD eFFicacY
Frequency, severity, and duration of AEs during the study, such as episodes of serious infection, immunosuppression-related complications, and deviations from the study protocol for any reason were recorded in the safety analysis. Hematology, biochemistry, urinalysis, and microbiology tests were performed on day 7 and, then, twice a week for the first 3 weeks after LT. Afterward, they were performed at 3, 6, 12, and 24 months. Clinically suspected acute rejection was confirmed by biopsy and graded according to the Banff criteria. (18) 
statistical analYsis
The trial was designed as a classical single-stage phase 2 study with the following assumptions: the inactivity cutoff was ≤60% and the activity cutoff was ≥75%.
Hence, the hypotheses of interest were null hypothesis (H0) (r ≤ 60%) against alternative hypothesis (HA) (r ≥ 75%), where r was the proportion of patients who were tBPAR free at the 3-month visit. The type I error rate (α probability of accepting an insufficiently active treatment, a false-positive outcome) was set at 2.5%; the type II error rate (ß probability of rejecting an active treatment, a false-negative outcome) was set at 20%.
Under these assumptions, 80 patients were required for the analysis. Treatment efficacy was calculated by the number of tBPAR-free patients at 3 months after randomization: If this number was at most 56, the treatment was defined as insufficiently active; if it was at least 57, the treatment was declared as sufficiently active. The target error rate was 0.200 with an actual error rate of 0.182. The size of the control group was set as half of the size of the study group (40 patients). No criteria were defined to assess the "activity" in this group.
The efficacy analysis and renal function assessment were performed on all randomized patients until the 24-month visit or the date of dropout. Safety analysis included all randomized patients who received at least 1 dose of study medication.
Because an ex-post analysis identified a subgroup of patients who minimized TAC before reaching EVR target concentration, we also performed a sensitivity per protocol analysis: The study group was further stratified into per protocol-immunosuppressed and deviator patients.
All continuous variables are presented as median and interquartile range, whereas categorical and nominal variables are presented as frequencies and percentages. For subgroup comparisons, quantitative variables were compared using the Student t or Wilcoxon rank sum tests, and categorical variables were compared using the χ 2 or Fisher's exact tests, as appropriate.
The follow-up period started from randomization until date of graft failure or death or latest follow-up visit (24-month visit or end of study). The length of follow-up and time-to-event are expressed as median and ranges. Time-to-event curves were calculated using the Kaplan-Meier method and compared with the log-rank test. All analyses were performed using JMP, version 9.0 (SAS Institute Inc., Cary, NC) and STATA, version 13.0 (StataCorp, College Station, TX).
Results
stUDY pOpUlatiOn
From March 2010 to August 2014, 140 patients were enrolled in the study: 93 were randomized in the EVR group and 47 were in the control group. Patients were well balanced in terms of indication to transplantation, age, sex, main donor characteristics, main laboratory parameters, and hepatic and renal function at randomization (Table 1) . During the first 3 months after randomization, 17 (12.1%) patients were withdrawn from the study: 1 (0.7%) patient died, 2 (1.4%) lost their graft, and the others prematurely ended the trial for AEs or protocol violations. Data from 1 patient in the study group were not recorded in the electronic case report form; thus the patient was considered as a dropout. None of these patients had tBPAR in the first 3 months. These 17 patients were maintained in the intention-to-treat analysis.
priMarY enDpOint tBPAR
During the first 3 months after randomization, the rate of tBPAR was 12.9% (12/93) in the EVR group and 4.3% (2/47) in the control group (P = 0.09). After a sensitivity per protocol analysis, we found that 20 patients in the EVR group (21%) minimized TAC before reaching EVR target concentration, thus undergoing a potentially suboptimal immunosuppression. Therefore, in the context of an ex-post analysis, the EVR group was further divided into per protocolimmunosuppressed patients (n = 73, 78%) and deviator patients (n = 20, 22%). At the 3-month visit, the tBPAR rate was 6/73 (8.22%) in per protocol-immunosuppressed patients and 6/20 (30%) in deviator patients (P = 0.02), whereas it was similar in the per protocol-immunosuppressed group (6/73) and in the control group (2/47; P = 0.43). In the control group, only 8 (17%) patients had a TAC level lower than 6 ng/mL at 3 months. No patients had a TAC level >12 ng/mL. Severity of tBPAR was similar between the 2 groups (median Histopathology Activity Index [HAI] score 4/9). The time-varying probability of tBPAR at 1 month, 3 months, and 1 year were 2.7%, 6.9%, and 14.2%, respectively, in the per protocol-immunosuppressed group; 15%, 30%, and 30%, respectively, for the deviator group; and 4.3%, 4.3%, and 4.3%, respectively, in the control group (P = 0.01; Supporting 
secOnDarY enDpOints
Composite Failure Rate
The proportions of composite failure endpoint-free patients (without tBPAR plus graft or patient failure) were 85% in the EVR group versus 94% in the control group at 3 months after randomization, 77% versus 94%, respectively, at 12 months, and 77% versus 87%, respectively, at 24 months (P = 0.15).
In a subgroup analysis, these proportions at 3, 12, and 24 months were 89%, 81%, and 81%, respectively, in the EVR per protocol-immunosuppressed group (P = 0.34 versus control group) and 70%, 65%, and 65%, respectively, in the deviator group (P = 0.04 versus control group; Fig. 2 ).
Graft and patient survival rates at 12 months were comparable between EVR and control groups (P = 0.66; Supporting Fig. 2 ), and at 24 months, it was similar between EVR subgroups (per protocolimmunosuppressed and deviators) and the control group (P = 0.90; P = 0.62; Supporting Figs. 3 and 4).
Renal Function
Before transplantation, at the time of randomization, and 1 week after randomization, eGFR-MDRD-4 was similar among the 2 groups. However, starting from the second week after randomization, a significantly worse eGFR-MDRD-4 was observed in the control group until the end of the study (Fig. 3A) . Median difference in eGFR-MDRD-4 between the 2 groups was 20, 24, 32, and 36 mL/minute/1.73 m 2 at 1 month, 6 months, 12 months, and 24 months of Original article | 247 248 | Original article follow-up, respectively. These differences remained statistically significant over time and also when only per protocol-immunosuppressed patients were considered (Fig. 3B) . At LT, 26.3%, 47.4%, and 26.3% of patients in the EVR group and 18.2%, 63.6%, and 18.2% in the control group had chronic kidney disease (CKD) stage 1, 2, and 3, respectively (according to Kidney Disease Outcomes Quality Initiative criteria). At 1 year from LT, 52.5%, 30%, and 17.5% of patients in the EVR group and 31.6%, 36.8%, and 31.6% in the control group had CKD stage 1, 2, and 3, respectively. No CKD stage 4 and 5 patients were reported before and 1 year after LT.
Acute renal failure requiring renal replacement therapy occurred in 4.3% (4/93) of patients in the EVR group and in 10.6% of patients (5/47) in the control (P = 0.11). Nearly all of these events occurred in the early posttransplant period (within the first 2 weeks) with only 1 case reported at 2 years after transplant, which was related to a urinary tract infection.
At randomization, 3 (3.2%) patients in the EVR group had a mild grade of proteinuria (defined as urine protein <0.5 g/day) versus 2 (4.2%) patients in the control group. During the follow-up, 13.9% (13/93) of patients in the EVR group and 12.7% (6/47) in the control group presented at least 1 episode of urine test with significant proteinuria (P = 0.54).
TAC Discontinuation Rate/Study Discontinuation Rate
The rate of patients in monotherapy with EVR was 11.8% (11/93) at 1 month, 37.6% (35/93) at 3 months, 43% (40/93) at 12 months, and 46% (43/93) at 24 months after transplantation. The tBPAR rates at 3 months and 1 year were 11.4% (4/35 patients) and 22.5% (9/40), respectively, in the monotherapy group, and 13.8% (8/58) and 13.2% (7/53), respectively, in those who did not reach monotherapy (P = 0.33; P = 0.20). At 24 months, the proportion of patients who continued the study was 57% in the EVR group and 66% in the control group (P = 0.26; Supporting 
Adverse Events
The overall proportion of patients with at least 1 AE at 24 months (any or serious) was similar between groups but patients on EVR presented more dyslipidemia and incisional hernias (IHs), whereas patients on TAC presented more neurological disorders (Table 2) . During the follow-up, pathological cholesterol levels (17.5% versus 6.9%; P = 0.07) and high low-density lipoprotein (LDL; 37.1% versus 6.7%; P = 0.01) were reported in the EVR group. At 12 months, mean (±standard deviation) values of total cholesterol were 199 (±43) mg/dL in the study group versus 147 (±51) mg/dL in the control group (P < 0.001) and 121 (±38) mg/dL versus 99 (±34) mg/dL for LDL cholesterol levels (P = 0.03). No differences were observed with regard to hypertriglyceridemia (16.1% versus 8.5%; P = 0.10) and high-density lipoprotein levels (30.1% versus 17%; P = 0.15). Patients in the EVR group more frequently presented with wound-healing complications (18.2% versus 0%; P < 0.05) and IHs (25.8% versus 6.3%; P < 0.05). Neurological disorders, such as hallucinations, delirium, disorientation, agitation, confusion, depression, anxiety, and mood alteration, were more frequent in the control group (13.9% versus 31.9%; P < 0.05). The incidence of infections was similar between the 2 groups, although more infections defined as serious AEs (eg, infections leading to a longer hospital stay, inducing life-threatening Original article | 249 conditions, or requiring intensive care unit stay) were reported in the control group (11.8% versus 27.6%; P < 0.05). There were 4 patients (8.5%) who prematurely dropped out from the study because of TAC toxicity in the control group.
Discussion
It is well accepted that the post-LT end-stage renal disease rate has risen significantly since the implementation of the Model for End-Stage Liver Disease (MELD)-based allocation policy. (19) The cumulative incidence of stage ≥4 CKD within 5 years from LT is 15%-25% with a relevant impact on early and late patient survival. (20) Different strategies, including the use of induction therapy at the time of transplantation followed by delayed and low-dose CNIs (21) and CNI minimization/withdrawal associated with the initiation of a different class of immunosuppressive agents, have been investigated to overcome CNI-induced renal toxicity. (22) Studies on EVR introduction after de novo LT confirmed the safety of a minimization/withdrawal mTOR inhibitor-based approach. (16, 23, 24) To preserve renal function as early as possible in the delicate phase of posttransplant recovery, a very early introduction of EVR with CNI (cyclosporine A [CsA]) withdrawal was described by Masetti et al. (15) In this prospective, randomized, single-center study, the authors introduced EVR (initial dose 2.0 mg/day) at day 10 to achieve a target trough of 6-10 ng/mL. On day 30, CsA was abruptly discontinued, and EVR was adjusted to reach a trough level of 8-12 ng/mL for 6 months and, thereafter, maintain at 6-10 ng/ mL. Since the first month after LT, renal function was statistically better in the EVR group compared with the cyclosporine group, and mean eGFR-MDRD-4 remained higher in the EVR group at 6 and 12 months after transplantation, with similar incidences of acute cellular rejection and patient and graft survival. (15) On the basis of our knowledge, this is the first prospective, multicenter, randomized study on a relatively large population that introduced EVR at POD 7 with the aim to minimize TAC trough levels as soon as possible. So far, only Levy et al. in a phase 2 study investigated the safety of very early EVR introduction (POD 0) in LT patients. (13) Two elements of originality characterize our trial: the very early introduction of EVR (even more anticipated than the study by Masetti et al. 15 ) and the combination EVR-TAC versus TAC plus steroids (standard regimen at the time of study design) never investigated previously in such an early posttransplant phase (the phase 2 study by Levy et al. starting EVR on day 0 was associated with CsA). (13) In this setting, our data showed a significant difference in renal function, as early as 2 weeks after TAC reduction (POD 21) in the EVR-TAC minimization group. A similar finding was described by Saliba et al. (25) reporting higher eGFR from week 2 after the randomization for the EVR group versus TAC. Per our knowledge, these results are the earliest significant improvement in renal function in the postoperative phase reported for a minimization strategy, which may be extremely important in complex patients whose early multiorgan dysfunction may affect the overall outcome.
As far as efficacy is concerned, the study showed that even though in the EVR group there was a trend toward a higher prevalence of tBPAR (P = 0.09, the sample size was properly powered to obtain a sufficiently active treatment), the overall tBPAR rate (12.9%) was <25% at 3 months after transplantation in the study group. The SIMCER study (25) reported a higher incidence of tBPAR in the EVR cohort (P = 0.02) in a 24-month follow-up.
However, in some patients, TAC was minimized when EVR had not reached the optimal trough concentration, thus leading to potentially suboptimal immunosuppression: This may partially explain why the tBPAR rate was significantly higher in deviator patients than those in the control group. Nevertheless, in patients who reached the EVR trough concentration target (per protocol-immunosuppressed group), the tBPAR rate was similar as with the standard TAC, and we even observed a significant advantage in renal function (eGFR-MDRD-4). This improvement in renal function was observed as early as POD 21 and continued until the end of the study not only in the per protocol-immunosuppressed subgroup, but also in the whole EVR-treated population.
The incidence of AEs was similar between groups except for wound complication, IH, dyslipidemia, proteinuria (more frequent in the study group), and neurological disorders (more frequent in the control group). The use of mTOR inhibitors is an important independent risk factor for IH after LT. (15, 26, 27) However, previous studies did not report such a significant difference when mTOR inhibitors were introduced early after transplantation. (15, 28) IHs are commonly reported after LT with a frequency range of 1.7%-34.3%. (27) (28) (29) In our study, in both arms, the frequency of IH was in that range, but the prevalence was extremely variable across centers (range 0%-60%), thus suggesting the role of technical risk factors mainly affected the pathophysiology of posttransplant wound complications. Adjustment of surgical techniques in view of wound healing should be contemplated when EVR is introduced early after transplantation. (26) EVR clearly predisposes patients to wound complications, but surgical technique details could potentially mask or favor this predisposition.
The mTOR pathway is also involved in the regulation of both anabolic (lipogenesis, adipogenesis, and fatty acid esterification) and catabolic (lipolysis and β-oxidation) processes. (30) Increase in serum cholesterol, triglyceride, and glucose have been commonly observed in clinical trials with mTOR inhibitors (30) (31) (32) and are consistent with our results. As expected, (6, 22) the overall incidence of proteinuria was higher in the study group (13.9% versus 12.7%; P = not significant), and it was the reason for EVR discontinuation in 5 patients. As previously reported, neurological disorders were significantly higher in the standard CNI therapy group, confirming that CNIs showed higher neurotoxicity than mTOR inhibitors. (33) The present study has some limitations. Although this is a randomized clinical trial, this study was constructed as a classical single-stage phase 2 study. The open-label design of the study and the need to adjust TAC and EVR doses may have biased the report of AEs. Most clinicians were having their first experience with EVR, and this may have more easily prompted the need for a biopsy, potentially increasing the detection of acute cellular rejection in the study group. Moreover, many laboratories provide EVR levels 2-4 days after a blood sample. These problems made it difficult to rapidly reach EVR target levels in a short period of time as scheduled from the protocol. These issues may also explain why we had a considerable proportion of deviators and a low rate of TAC withdrawal representing the main study limitation. Furthermore, despite the fact that differences in cholesterol and triglyceride levels may be influenced by the use of statins or fibrates, concomitant therapies were not available for all randomized patients.
The incidence of tBPAR is usually reported in the literature at 12 months after LT. However, many studies underline that the majority of tBPAR occurs early (initial 3 months). (34) Because the main feature of this study is the early introduction of EVR (POD 7), a completely unexplored scenario when the study was designed, we considered 3 months as a valuable and safe efficacy endpoint.
The study schedule was designed and approved before the EVR pivotal study (H2304). That explains some differences with the current practice, like an initial dose of 3 mg/bid or 6-12 ng/mL target level. Thus, initial doses and target levels were chosen on the basis of kidney registration trials (A2306, A2307). (35) Furthermore, the baseline eGFR of randomized patients was close to normal values. It may be useful to analyze a subpopulation with poor renal function to verify the opportunity to anticipate EVR conversion also in this setting. A longer follow-up is required to better determine renal function improvement and may permit an assessment of other potential advantages of an mTOR inhibitor-based regimen, such as a decreased recurrence of HCC, although a recent finding did not support the prescription of EVR in HCC LT recipients due to no significant benefit in terms of tumor recurrence. (36) In conclusion, an immunosuppressive schedule with very early (7 days) introduction of EVR in association with TAC reduction and/or withdrawal was associated with a significant improvement of renal function as early as 3 weeks after transplantation and persisting up to 24 months. However, this regimen was associated with higher incidence of wound complications, lipid profile modifications, and proteinuria. A higher risk for tBPAR was recorded when TAC was minimized before EVR levels were optimal. This regimen may represent a suitable immunosuppressive approach when a very early postoperative protection of renal function is clinically crucial for patients. 
